Loading clinical trials...
Loading clinical trials...
A Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Napabucasin Protocols
Conditions
Interventions
Napabucasin
Nab-paclitaxel
+7 more
Locations
7
United States
Winship Cancer Institute, Emory University
Atlanta, Georgia, United States
Maine Center for Cancer Medicine
Scarborough, Maine, United States
OHSU Knight Cancer Institute
Portland, Oregon, United States
Centre Antoine Lacassagne
Nice, France
Kanagawa Cancer Center
Yokohama, Kanagawa, Japan
Kyorin University Hospital
Tokyo, Japan
Start Date
February 24, 2020
Primary Completion Date
May 15, 2021
Completion Date
May 30, 2021
Last Updated
November 8, 2023
NCT06359210
NCT07476495
NCT06868524
NCT05781295
NCT06193083
NCT07368582
Lead Sponsor
Sumitomo Pharma America, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions